laromustine and Glioma

laromustine has been researched along with Glioma* in 1 studies

Other Studies

1 other study(ies) available for laromustine and Glioma

Article	Year
Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program. Pediatric blood & cancer, 2008, Volume: 51, Issue:3 VNP40101M is a novel alkylating agent that yields two reactive compounds (a chloroethylating species and methylisocyanate) and has demonstrated activity against a wide spectrum of tumor xenografts. VNP40101M was tested against an in vivo panel of five pediatric brain tumor xenografts at a dose of 18 mg/kg/day administered for 5 days. O-6-methylguanine-DNA methyltransferase (MGMT) levels of xenografts were assessed by Western blot analysis. Only one xenograft (GBM2), which lacked detectable MGMT expression, demonstrated an objective response to VNP40101M. VNP4010M antitumor activity was observed only in the absence of MGMT expression, with resistance to VNP4010M seen even with low MGMT expression. Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Evaluation, Preclinical; Female; Glioblastoma; Glioma; Hydrazines; Mice; Mice, Inbred Strains; O(6)-Methylguanine-DNA Methyltransferase; Sulfonamides; Transplantation, Heterologous; Treatment Outcome	2008

Article

Year

Initial testing of VNP40101M (Cloretazine) by the pediatric preclinical testing program.

Pediatric blood & cancer, 2008, Volume: 51, Issue:3

VNP40101M is a novel alkylating agent that yields two reactive compounds (a chloroethylating species and methylisocyanate) and has demonstrated activity against a wide spectrum of tumor xenografts. VNP40101M was tested against an in vivo panel of five pediatric brain tumor xenografts at a dose of 18 mg/kg/day administered for 5 days. O-6-methylguanine-DNA methyltransferase (MGMT) levels of xenografts were assessed by Western blot analysis. Only one xenograft (GBM2), which lacked detectable MGMT expression, demonstrated an objective response to VNP40101M. VNP4010M antitumor activity was observed only in the absence of MGMT expression, with resistance to VNP4010M seen even with low MGMT expression.

Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Drug Evaluation, Preclinical; Female; Glioblastoma; Glioma; Hydrazines; Mice; Mice, Inbred Strains; O(6)-Methylguanine-DNA Methyltransferase; Sulfonamides; Transplantation, Heterologous; Treatment Outcome

2008